[{"id":"42c51771-6ced-4902-9fd0-2fa649ac3732","acronym":"TranStar102","url":"https://clinicaltrials.gov/study/NCT04495296","created_at":"2021-01-18T21:32:44.326Z","updated_at":"2025-02-25T14:29:29.560Z","phase":"Phase 1/2","brief_title":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04495296 - TranStar102","lead_sponsor":"Suzhou Transcenta Therapeutics Co., Ltd.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • gemcitabine • paclitaxel • capecitabine • oxaliplatin • osemitamab (TST001)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 08/13/2020","start_date":" 08/13/2020","primary_txt":" Primary completion: 02/25/2025","primary_completion_date":" 02/25/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-10-21"},{"id":"fb28253b-a10c-4263-9209-514e35dbc316","acronym":"","url":"https://clinicaltrials.gov/study/NCT06093425","created_at":"2023-10-23T20:13:54.880Z","updated_at":"2024-07-02T16:35:32.402Z","phase":"Phase 3","brief_title":"Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma","source_id_and_acronym":"NCT06093425","lead_sponsor":"Suzhou Transcenta Therapeutics Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • osemitamab (TST001)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 950","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2023-10-20"},{"id":"d43594a4-8a1d-44bc-a118-39c8ae2821d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05190575","created_at":"2022-01-13T13:56:13.559Z","updated_at":"2024-07-02T16:35:41.819Z","phase":"Phase 2","brief_title":"TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer","source_id_and_acronym":"NCT05190575","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e osemitamab (TST001)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 01/14/2022","start_date":" 01/14/2022","primary_txt":" Primary completion: 05/06/2023","primary_completion_date":" 05/06/2023","study_txt":" Completion: 05/06/2023","study_completion_date":" 05/06/2023","last_update_posted":"2023-07-27"}]